急性髓系白血病中的去甲基化药物与维奈克拉 - Suppr | 超能文献

Hypomethylating agents and venetoclax in acute myeloid leukemia.

作者信息

DiNardo Courtney D

机构信息

Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

出版信息

Clin Adv Hematol Oncol. 2021 Feb;19(2):82-83.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Hypomethylating agents and venetoclax in acute myeloid leukemia.急性髓系白血病中的去甲基化药物与维奈克拉

Clin Adv Hematol Oncol. 2021 Feb;19(2):82-83.

2

Venetoclax with decitabine or azacitidine for AML.维奈托克联合地西他滨或阿扎胞苷治疗急性髓系白血病

Lancet Oncol. 2018 Dec;19(12):e672. doi: 10.1016/S1470-2045(18)30824-6. Epub 2018 Nov 1.

3

Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.异基因造血干细胞移植后髓系恶性肿瘤复发的治疗：维奈托克联合低甲基化药物的回顾性多中心分析-代表德国合作移植研究组。

Ann Hematol. 2021 Apr;100(4):959-968. doi: 10.1007/s00277-020-04321-x. Epub 2020 Nov 16.

4

Updates on DNA methylation modifiers in acute myeloid leukemia.急性髓系白血病中 DNA 甲基化修饰物的研究进展。

Ann Hematol. 2020 Apr;99(4):693-701. doi: 10.1007/s00277-020-03938-2. Epub 2020 Feb 6.

5

Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.优化新型老年急性髓系白血病患者联合低强度治疗方案中的维奈托克剂量：暴露反应分析。

Hematol Oncol. 2019 Oct;37(4):464-473. doi: 10.1002/hon.2646. Epub 2019 Aug 2.

6

Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia.维奈托克联合低甲基化药物治疗低危急性髓系白血病的疗效

Am J Hematol. 2021 Mar 1;96(3):E59-E63. doi: 10.1002/ajh.26057. Epub 2020 Dec 8.

7

A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.一项在门诊环境中进行的 Venetoclax 联合阿扎胞苷或地西他滨治疗急性髓系白血病患者的 3b 期研究。

Hematol Oncol. 2024 May;42(3):e3274. doi: 10.1002/hon.3274.

8

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。

Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.

9

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.维奈克拉与去甲基化药物联合治疗复发/难治性急性髓系白血病的疗效

Haematologica. 2018 Sep;103(9):e404-e407. doi: 10.3324/haematol.2018.188094. Epub 2018 Mar 15.

10

Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.白血病遗传学与复发/难治性急性髓系白血病对维奈托克和去甲基化药物反应的关联

Am J Hematol. 2019 Oct;94(10):E253-E255. doi: 10.1002/ajh.25567. Epub 2019 Jul 10.

引用本文的文献

1

Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies.BCL-2抑制剂与免疫疗法联合应用：血液系统恶性肿瘤的一种有前景的治疗策略。

Discov Oncol. 2024 Jul 26;15(1):311. doi: 10.1007/s12672-024-01161-3.